Recent advances in our understanding of cancer DNA and machine learning allow DELFI to dramatically reduce the cost of screening tests while increasing performance.ĮarlyDiagnostics, Inc USA Private EarlyDx is a spinoff company from UCLA and Stanford, with the goal of providing accurate, affordable, and non-invasive methods for early cancer detection and health monitoring. But without low-cost, high-performing, convenient tests, cancer screening rates have remained alarmingly low. Early cancer detection could save millions of lives and billions of dollars a year. IchorLabs technology has the potential for broad diagnostic applicability.ĭelfi Diagnostics USA Private Delfi Diagnostics is developing an innovative blood test for detection and interception of cancer when it is most curable. Our technology utilizes several features that allow high-yield capture of biomarkers present in small quantities from any body fluid resulting in increased accuracy of the liquid biopsy tests. When cancer is detected in the early stages the survival rate for patients is above 90%. High sensitivity liquid biopsy test could eventually lead to regular population-based screening for early-stage cancers. The primary goal of our patent-pending technology is to increase sensitivity of liquid biopsy tests and improve early cancer detection. IchorLabs Slovenia Private IchorLabs is a biotechnology company with the primary focus to improve current non-invasive diagnostic tests in the areas of oncology prenatal diagnostics and infectious diseases. VentureRadar Research / Company WebsiteĪssociated sectors: Life Sciences Early cancer detection Liquid Biopsy cfDNA Cancer detection Cancer Diagnostics Overall employee rating is 4.0 out of 5 (as of 18th Jun 2023) We aim to improve the efficiency and accuracy of liquid biopsy and consequently improve the survival rate of patients. Apostle develops a best-in-class technique Apostle MiniMax TM to efficiently capture this cfDNA from a standard blood draw as well as other innovations in the space of liquid biopsy. cfDNA is present in very small amounts in the blood plasma. We partner with the Beckman Coulter Life Sciences to offer our innovative technologies automated or manual which have been featured in Science. Apostle invents best-in-class cfDNA technologies used in a liquid biopsy.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |